Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.849863
Keywords
proteasome; antigen processing; peptide splicing; adoptive T cell transfer; prediction algorithms; neosplicetopes
Categories
Funding
- Berlin Institute of Health [CRG-1]
- Einstein Stiftung [A- 2013-174]
- Berliner Krebsgesellschaft
Ask authors/readers for more resources
Proteasome generates spliced peptides through a reverse proteolysis reaction, potentially holding therapeutic and immune relevance. However, there is controversy surrounding the frequency, abundance, and therapeutic applicability of spliced peptides. Nevertheless, the search for tumor and patient-specific neosplicetopes still seems valuable.
Proteasome generates spliced peptides by ligating two distant cleavage products in a reverse proteolysis reaction. The observation that CD8+ T cells recognizing a spliced peptide induced T cell rejection in a melanoma patient following adoptive T cell transfer (ATT), raised some hopes with regard to the general therapeutic and immune relevance of spliced peptides. Concomitantly, the identification of spliced peptides was also the start of a controversy with respect to their frequency, abundancy and their therapeutic applicability. Here I review some of the recent evidence favoring or disfavoring an immune relevance of splicetopes and discuss from a theoretical point of view the potential usefulness of tumor specific splicetopes and why against all odds it still may seem worth trying to identify such tumor and patient-specific neosplicetopes for application in ATT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available